Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin, Irinotecan, and Bevacizumab in Extensive Stage SCLC
NCT00118235Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2004
- Primary completion
- Apr 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in small cell lung cancer (SCLC), sponsored by National Cancer Institute. Primary endpoints: Overall Survival at 4 years and Failure-Free Survival at 4 years. Started Dec 2004; status: completed.
02
Drugs
bevacizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00118235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118235.